Cefonicid
Cefonicid is a long-acting cephalosporin antibiotic. Cefonicid also acts as a noncompetitive class I β-lactamase inhibitor with a Ki value of 0.8 μM. Cefonicid exhibits broad-spectrum antimicrobial activity and is effective against a variety of Gram-positive and Gram-negative bacteria. Cefonicid can be used for research on infections.
For research use only. We do not sell to patients.
- CAS No.: 61270-58-4
- Formula: C18H18N6O8S3
- Molecular Weight:542.57
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Cefonicid (25-200 mg/L; 3-6 days) dose-dependently inhibits the proliferation of human PBMCs stimulated by FLU, XENO, ALLO, and PHA (HY-N7038)[1].
Cefonicid (0-200 mg/L; 7 days) dose-dependently inhibits IL-2 production by human PBMC stimulated with FLU, XENO and ALLO[1].
Cefonicid (0-24 h) exhibits concentration-dependent bactericidal activity against Klebsiella pneumoniae strain 2603 in vitro, with an MIC of 0.25 mg/L[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
In Vivo
Cefonicid (40 mg/kg; single dose) exhibits excellent protective effects against S. aureus, E. coli, P. mirabilis, and K. pneumoniae infections in mice[4].
Cefonicid exerts excellent preventive protective effects against surgical wound infections in mice, with an ED50 value of ≤2.1 mg/kg against Gram-negative bacilli and an ED50 value ranging from 3.7 to 8.7 mg/kg against S. aureus[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hartley (female, 220-250 g)[3]
-
Dosage:15 mg/kg
-
Administration:i.p.; 2 doses (immediately and 24 hours post-challenge)
-
Result:Showed similar lung bacterial counts to infected untreated controls at 0 and 1 hour post-challenge.
Reduced lung bacterial counts significantly compared to infected untreated controls starting at 6 hours post-challenge, with significant reductions also seen at 24 and 48 hours post-challenge.
Chemical Information
-
CAS No. 61270-58-4
-
Molecular Weight 542.57
-
Formula C18H18N6O8S3
-
SMILES
O=C(O)C(N12)=C(CSC3=NN=NN3CS(=O)(O)=O)CS[C@]2([H])[C@H](NC([C@H](O)C4=CC=CC=C4)=O)C1=O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Gram Staining of Tissue Sections
Gram staining of tissue sections is a histochemical technique used to differentiate Gram-positive and Gram-negative bacteria within histological specimens based on differences in bacterial cell wall structure and dye retention, adapted from classical bacteriological Gram staining into tissue-compatible “histological Gram stain” variants. In tissue applications, modifications of the Brown-Hopps and Brown-Brenn methods are commonly used to improve differentiation of microorganisms embedded within host connective tissue and to reduce overstaining or loss of Gram-negative signal, which are known limitations of earlier approaches. The principle relies on crystal violet-iodine complex retention in Gram-positive organisms and subsequent decolorization and counterstaining steps that allow contrast visualization of Gram-negative organisms against tissue background.
Purity & Documentation
References
[1]. Villa ML, et al. Interference of cephalosporins with immune response: effects of cefonicid on human T-helper cells. Int J Immunopharmacol. 1991;13(8):1099-1107. [Content Brief]
[4]. Saltiel E, et al. Cefonicid. A review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1986;32(3):222-259. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)